Results 201 to 210 of about 1,712,707 (295)

An Effector TaCRVP From Tuta Absoluta Oral Secretion Impairs H2O2‐Mediated Plant Defense by Targeting Tomato SlCAT2

Advanced Science, EarlyView.
The Tuta absoluta salivary effector TaCRVP subverts tomato immunity by hijacking host catalase SlCAT2. Through a sophisticated dual mechanism, TaCRVP simultaneously promotes SlCAT2 tetramerization for activation and blocks its SlAdBiL‐mediated degradation for stabilization.
Jianquan Yan, Youdan Zhang, Zhujun Wang, Huatao Tang, Huiping Liu, Zi Chen, Shuai Liu, Jiayi Shi, Lu Peng, Youming Hou   +9 more
wiley   +1 more source

Ligase-catalyzed transcription and reverse-transcription of XNA-containing nucleic acid polymers using T3 DNA ligase. [PDF]

Chem Sci
Khamissi N, Korfmann C, Chaudhry A, Hili R.   +3 more
europepmc   +1 more source

Autophagy Orchestrates Anti‐Tumor Immunity to Enhance Chemosensitivity via the FBXW2/C/EBPβ/TIMP‐2 Axis in Colorectal Cancer

Advanced Science, EarlyView.
Chemotherapy leverages tumor‐cell autophagy to reshape the colorectal cancer immune microenvironment. Autophagy degrades FBXW2 to promote C/EBPβ‐mediated TIMP‐2 transcription and MMP‐9 suppression, driving intra‐tumoral CD8+ T‐cell infiltration. Targeting MMP‐2/9 or restoring TIMP‐2 overcomes chemo‐resistance in autophagy‐deficient tumors. ABSTRACT The
Bing Cheng, Chaoying Wei, Zhitong Niu, Jinxin Chen, Guojie Long, Yingzhen Weng, Qiufeng Liu, Yue Jiang, Panpan Wang, Ronghua Zhang, Qiang Yu, Xiaojian Wu, Wenyu Wang   +12 more
wiley   +1 more source

The Contribution of DNA Ligase 4 Polymorphisms to Colorectal Cancer. [PDF]

In Vivo
Deng Y, Ke TW, Yueh TC, Chin YT, Wang YC, Hung YC, Mong MC, Yang YC, Wu WT, Chang WS, Gu J, Bau DT, Tsai CW.   +12 more
europepmc   +1 more source

GSTM4 Suppresses Prostate Cancer Progression by Targeting TRIM27‐mediated ACLY Ubiquitination and Lipid Metabolism

Advanced Science, EarlyView.
GSTM4 enhances the interaction between ACLY and the E3 ubiquitin ligase TRIM27, thereby increasing K48‐linked ubiquitination at the K554 site of ACLY and promoting its degradation. Consequently, GSTM4 regulates lipid synthesis, as well as the proliferation and metastasis of PCa cells, by modulating ACLY stability.
Kang‐Ping Xiong, Fei Liu, Wang Wang, Gang Wang, Kai‐Yu Qian, Sheng Tu, Si‐Ming Chen, Hui‐Min Xu, Shan‐Shan Zhang, Yong Li, Xing‐Huan Wang, Hong Weng   +11 more
wiley   +1 more source

Impact of DNA ligase inhibition on the nick sealing of polβ nucleotide insertion products at the downstream steps of base excision repair pathway. [PDF]

Mutagenesis
Almohdar D, Kamble P, Basavannacharya C, Gulkis M, Calbay O, Huang S, Narayan S, Çağlayan M.   +7 more
europepmc   +1 more source

Altered DNA ligase activity in human disease. [PDF]

Mutagenesis, 2020
Tomkinson AE, Naila T, Khattri Bhandari S.   +2 more
europepmc   +1 more source

Uhrf1‐Mediated PKM2 Degradation via Ubiquitination Alleviates Inflammation and Pyroptosis in Inflammatory Bowel Disease

Advanced Science, EarlyView.
Uhrf1‐mediated PKM2 ubiquitination and degradation repressed the nuclear translocation of PKM2, and EPT served as a molecular glue capable of targeting the Uhrf1–PKM2 complex to alleviate the IBD course, suggesting that the Uhrf1–PKM2 axis was a previously unrecognized strategy for treating IBD.
Juan Zhang, Xin‐Rong Xu, Hui‐Lin Zhang, Qi‐Meng Zhu, Xin‐Yuan Li, Xi‐Peng Shang, Jing‐Hui Du, Christophe Morisseau, Feng Qiu, Cheng‐Peng Sun   +9 more
wiley   +1 more source

NAD+ is not utilized as a co-factor for DNA ligation by human DNA ligase IV. [PDF]

Nucleic Acids Res, 2020
Zhao B, Naila T, Lieber MR, Tomkinson AE.   +3 more
europepmc   +1 more source

The Cancer Cell Metabolic Reprogramming Remodels the Tumor Microenvironment: Molecular Mechanisms and Therapeutic Strategies

Advanced Science, EarlyView.
This review elucidates how cancer cell metabolic reprogramming—across glucose, lipid, amino acid, and nucleotide pathways—remodels the tumor microenvironment to suppress anti‐tumor immunity and promote immune escape. Targeting these metabolic axes offers promising strategies to overcome immunotherapy resistance and enhance cancer treatment.
Guoqing Xiang, Zhicheng Zhou, Xue Jiang, Zhenguang Du, Yangyang Zhan, Xinli Liu   +5 more
wiley   +1 more source